Cargando…
In vivo therapy of a murine B cell tumor (BCL1) using antibody-ricin A chain immunotoxins
Prolonged remissions were induced in mice bearing advanced BCL1 tumors by the combined approach of nonspecific cytoreductive therapy and administration of a tumor-reactive immunotoxin. Thus, the vast majority of the tumor cells (approximately 95%) were first killed by nonspecific cytoreductive thera...
Formato: | Texto |
---|---|
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
1982
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2186702/ https://www.ncbi.nlm.nih.gov/pubmed/6804591 |
Ejemplares similares
-
Cytotoxicity of a cell-reactive immunotoxin containing ricin A chain is potentiated by an anti-immunotoxin containing ricin B chain
Publicado: (1984) -
The effect of ricin B chain on the intracellular trafficking of an A chain immunotoxin.
por: Timar, J., et al.
Publicado: (1991) -
BCMab1-Ra, a novel immunotoxin that BCMab1 antibody coupled to Ricin A chain, can eliminate bladder tumor
por: Li, Chong, et al.
Publicado: (2016) -
Pharmacokinetic studies in mice with ICI D0490, a novel recombinant ricin A-chain immunotoxin.
por: Calvete, J. A., et al.
Publicado: (1993) -
Heterogeneous response of individual multicellular tumour spheroids to immunotoxins and ricin toxin.
por: Chignola, R., et al.
Publicado: (1995)